New drug approved for soft-tissue cancer

(HealthDay)—The chemotherapy drug Yondelis (trabectedin) has been approved by the U.S. Food and Drug Administration to treat certain soft-tissue sarcomas (STS) that have spread or can't be treated by surgery.

Oct 23, 2015
popularity10 comments 0

Team studies point to clinical advantages of proton therapy

The search for evidence to support the growing use of proton therapy for more cancers at Penn Medicine continues to uncover valuable findings. New data from clinical trials conducted at the Robert Proton Therapy Center demonstrate ...

Oct 19, 2015
popularity62 comments 0

A sarcoma (from the Greek sarx (σάρκα) meaning "flesh") is a cancer that arises from transformed cells of mesenchymal origin. Thus, malignant tumors made of cancerous bone, cartilage, fat, muscle, vascular, or hematopoietic tissues are, by definition, considered sarcomas. This is in contrast to a malignant tumor originating from epithelial cells, which are termed carcinoma. Sarcomas are quite rare - common malignancies, such as breast, colon, and lung cancer, are almost always carcinoma.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Functional human liver cells grown in the lab

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. ...

Combination therapy can prevent cytostatic resistance

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

New strategy for treating arthritis discovered

Arthritis patients could one day benefit from a novel form of medicine, according to researchers at Queen Mary University of London (QMUL). Their early study indicates that arthritic cartilage, previously thought to be impenetrable ...